Digest Network Come funziona
Network
/
Società
Id
Non verificato

Idorsia Pharmaceuticals Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceutica

65 comunicati stampa

Guarda tutti i comunicati
09/03/2026
Farmaceutica
Annunci Economici
Idorsia expands QUVIVIQ’s global footprint through new partnership with Pharmalink
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmaceutica
Annunci Economici
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
12/02/2026
Farmaceutica
Annunci Economici
Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/02/2026
Farmaceutica
Annunci Economici
Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
29/01/2026
Farmaceutica
Annunci Economici
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmaceutica
Annunci Economici
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/01/2026
Farmaceutica
Annunci Economici
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
11/01/2026
Farmaceutica
Annunci Economici
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/01/2026
Farmaceutica
Annunci Economici
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/01/2026
Farmaceutica
Annunci Economici
Idorsia’s daridorexant in women during menopausal transition age with insomnia
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0